D Langleben
Affiliations: | McGill University, Montreal, QC, Canada |
Area:
Pathology, Animal Physiology Biology, Cell BiologyGoogle:
"D Langleben"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Benzidia I, Robitaille C, Abualsaud A, et al. (2023) Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension. Thrombosis Research. 229: 139-145 |
| Benza RL, Langleben D, Hemnes AR, et al. (2022) Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Review : An Official Journal of the European Respiratory Society. 31 |
| Langleben D, Orfanos SE, Fox BD, et al. (2022) The Paradox of Pulmonary Vascular Resistance: Restoration of Pulmonary Capillary Recruitment as a for True Therapeutic Success in Pulmonary Arterial Hypertension. Journal of Clinical Medicine. 11 |
| Humbert M, Simonneau G, Pittrow D, et al. (2022) Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 41: 716-721 |
| Benza RL, Ghofrani HA, Grünig E, et al. (2021) Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation |
| Hoeper MM, Al-Hiti H, Benza RL, et al. (2021) Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. The Lancet. Respiratory Medicine |
| Ghofrani HA, Gomez Sanchez MA, Humbert M, et al. (2020) Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine. 178: 106220 |
| Hoeper MM, Gomez Sanchez MA, Humbert M, et al. (2020) Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine. 177: 106241 |
| Simonneau G, Ghofrani HA, Corris PA, et al. (2020) Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. Pulmonary Circulation. 10: 2045894020973124 |
| Klinger JR, Chakinala MM, Langleben D, et al. (2020) Riociguat: clinical research and evolving role in therapy. British Journal of Clinical Pharmacology |